SFS
AIMT

Sowell Financial Services’s Aimmune Therapeutics AIMT Stock Holding History

Sowell Financial Services’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-58
Closed -$2K – 2951
2020
Q3 		$2K Sell
58
-476
-89% -$10.1K ﹤0.01% 2305
2020
Q2 		$9K Sell
534
-1,832
-77% -$31.1K ﹤0.01% 1749
2020
Q1 		$34K Buy
2,366
+172
+8% +$4.4K ﹤0.01% 1192
2019
Q4 		$73K Buy
2,194
+2,016
+1,133% +$56.4K 0.01% 1007
2019
Q3 		$4K Buy
+178
New +$3.63K ﹤0.01% 1893

Sowell Financial Services's AIMT Position: Q4 2020 in Review

Sowell Financial Services sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 58 shares — an estimated $2K sold.

Sowell Financial Services first reported a position in AIMT in Q3 2019 and held it in 5 quarters. The position peaked at $73K in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Sowell Financial Services reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Sowell Financial Services sold 58 Aimmune Therapeutics shares in Q4 2020, an estimated $2K.
  • Sowell Financial Services first reported a position in Aimmune Therapeutics in Q3 2019 and held it in 5 quarters.
  • Sowell Financial Services's Aimmune Therapeutics position peaked at $73K in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Sowell Financial Services's 13F filing for Q4 2020, filed 13 Jan 2021.